ClinicalTrials.gg
CompletedNCT06238024IRISUpdated Sep 25, 2024

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

A Phase 2/3 interventional study of Tocilizumab and NaCl 0.9% 100ml in Interleukin-6, Ischemic Stroke and Endovascular Treatment, sponsored by Suzhou Municipal Hospital of Anhui Province. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Suzhou Municipal Hospital of Anhui Province · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Enrollment
417th of 566
108 · median 271
Started
2024
with 102 others
Phase 2/3
25 of 754
9 open now
Registered
426th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 417th largest by enrollment of the 566 interventional ones that give a count, is one of 103 that started in 2024, is one of 25 in phase 2/3, and was the 426th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Read the detailed description

Vascular recanalization techniques, including thrombolysis and thrombectomy, have become the mainstay of treatment for acute ischemic stroke. However, some patients still experience poor prognosis, with ineffective recanalization and reperfusion brain injury being the major contributors to unfavorable outcomes. Studies have indicated that tocilizumab, used in ST-segment elevation and non-ST-segment elevation myocardial infarction, exhibits anti-inflammatory and myocardial protective effects. Nevertheless, whether tocilizumab can provide neuroprotection in the early stages of acute large vessel recanalization remains uncertain. Given the above evidence, the aim of this study was to investigate whether combination therapy with tocilizumab in the early phase of recanalization of acute large vessel occlusion could further exert a beneficial effect and thus improve the poor prognosis of patients.

03

Conditions studied

  • Interleukin-6
  • Ischemic Stroke
  • Endovascular Treatment

Browse trials for

Keywords

  • Acute ischemic stroke
  • Tocilizumab
  • Neuroprotection
  • Outcome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years.

    1. Acute ischemic stroke caused by occlusion of intracranial segment of the internal carotid artery, middle cerebral artery M1, or M2 segment.
    2. NIHSS ≥ 6.
    3. Meeting the criteria of endovascular treatment:

      ① ASPECTS score ≥ 6, possibile to start endovascular treatment within 6 hours from stroke onset.

      ② Stroke onset between 6-16 hours, meeting DEFUSE-3 criteria (infarct core volume \< 70ml, mismatch ratio ≥ 1.8, and mismatch volume > 15ml), or DAWN criteria (NIHSS ≥ 10 and infarct core volume \< 31ml; or NIHSS ≥ 20 and infarct volume 31-51ml).

      ③ Stroke onset between 16-24 hours, meeting DAWN criteria (NIHSS ≥ 10 and infarct core volume \< 31ml; or NIHSS ≥ 20 and infarct volume 31-51ml).

      ④ When ASPECTS score is \< 6, meeting RESCUE-Japan LIMIT criteria (ASPECTS score 3-5; stroke onset within 6 hours or between 6-24 hours but no acute stroke signs on FLAIR), or ANGEL-ASPECT criteria (stroke onset within 24 hours, ASPECTS 3-5; or onset within 24 hours, ASPECTS 0-2 and infarct core volume 70-100 mL; or onset between 6-24 hours, ASPECTS > 5 and infarct core volume 70-100 mL), or SELECT2 criteria (ASPECTS 3-5; or infarct core volume greater than 50ml).

    4. Experimental drug administration had to be possible within 24 hours after stroke onset.
    5. Obtained from the patient or their legal representative.

Exclusion criteria

  1. Hemorrhagic diseases visible on head CT: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.

    1. Pre-stroke mRS score > 1.
    2. Known allergy to tocilizumab or .
    3. Known allergy to iodinated contrast agents.
    4. Anticipated difficulty in completing endovascular treatment due to vascular tortuosity.
    5. History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, thrombocytopenic diseases, etc.
    6. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite blood pressure control.
    7. Neutrophil \< 2×10 9/L.
    8. \< 100×10 9/L.
    9. Blood glucose \< 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400 mg/dl).
    10. Serum (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the .
    11. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated (eGFR) \< 60 mL/min.
    12. Pregnant, lactating, or planning pregnancy within 90 days.
    13. Severe mental disorders or inability to comply with and follow-up requirements due to dementia.
    14. Concurrent malignant tumors or severe systemic diseases with an expected survival of less than 90 days.
    15. Presence of diseases or use of drugs.
    16. Systemic infectious diseases
    17. Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Tocilizumab group

    Intravenously for more than 1 hour.

    Drug: Tocilizumab

  • Placebo comparator
    Control group

    Intravenously for more than 1 hour.

    Drug: NaCl 0.9% 100ml

Interventions

  • Single dose intravenous application

  • DrugNaCl 0.9% 100ml

    Single dose intravenous application

06

What researchers measure

Primary outcomes

  1. Change from baseline in infarct-core volume

    The infarct-core volume is determined by diffusion-weighted MRI, CT, or CTP images.

    Time frame: 72 hours

Secondary outcomes

  1. Early neurological improvement

    Decrease in National Institute of Health stroke scale (NIHSS) score of ≥8 or NIHSS score of 0-2 within 24 hours. NIHSS scores range from 0 to 42, with higher scores indicating greater neurologic deficit

    Time frame: within 24 hours

  2. NIHSS score

    National Institutes of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating greater neurologic deficit

    Time frame: 24 hours

  3. Proportion of successful reperfusion (mTICI 2b/3)

    mTICI denotes modified Treatment in Cerebral Ischemia classification, with scores ranging from 0 (no flow) to 3 (normal flow)

    Time frame: immediate postoperative

  4. Proportion of recanalization on follow-up CTA or MRA

    Time frame: 72 hours

  5. Incidence of cerebral hemorrhage

    Time frame: 72 hours

  6. Incidence of symptomatic cerebral hemorrhage

    Time frame: 72 hours

  7. NIHSS score

    National Institutes of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating greater neurologic deficit

    Time frame: 7 days

  8. Incidence of stroke-associated pneumonia

    Time frame: 7 days

  9. Incidence of decompressive craniectomy

    Time frame: 7 days

  10. Proportion of patients with functional independence (mRS 0-2)

    Scores on the modified Rankin scale range from 0 to 6, with higher scores indicating greater disability

    Time frame: 90 days

  11. Shift analysis of mRS score

    Scores on the modified Rankin scale range from 0 to 6, with higher scores indicating greater disability

    Time frame: 90 days

  12. Barthel Index

    The Barthel index is an ordinal scale for measuring performance of activities of daily living. Scores ranges from 0 to 20, with 0 indicating severe disability and 19 or 20 indicating no disability that interferes with daily activities.

    Time frame: 90 days

  13. EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D)

    EQ-5D is a standardized instrument for the measurement of health status. Scores range from -0.33 to 1.00, with higher scores indicating a better quality of life

    Time frame: 90 days

  14. Death

    Time frame: 90 days

  15. Adverse events and serious adverse events

    Time frame: 90 days

Other outcomes

  1. Change of hsCRP levels from admission to 72 hours

    Time frame: 72 hours

  2. Change of inflammatory blood biomarkers

    Interleukin-6

    Time frame: baseline, 24 hours, 48 hours, and 72 hours

07

Study locations

1 site
  • Suzhou Municipal Hospital of Anhui Province
    Suzhou, Anhui, China
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2024, 4 months.

Of 31 phase 2/3 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Feb 2, 2024
StartActual
Feb 2, 2024
Primary completionActual
Jun 25, 2024
CompletionActual
Sep 22, 2024
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238024
Lead sponsor
Suzhou Municipal Hospital of Anhui Province
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Feb 2, 2024
Primary completion
Jun 25, 2024
Completion
Sep 22, 2024
Last update
Sep 25, 2024

Study contacts

Chuanjie Wu, M.D.
study director · Xuanwu Hospital, Beijing
Zhengfei Ma, M.M.
study director · Suzhou Municipal Hospital of Anhui Province
Xunming Ji, M.D.
study chair · Xuanwu Hospital, Beijing
Xuehong Chu, M.D.
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion